United States

GlaxoSmithKline PLC (GSK)

GSK on New York Consolidated

26 Jul 2016
Change (% chg)

-- (--)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Latest Key Developments (Source: Significant Developments)

GlaxoSmithKline Plc declares dividend
Wednesday, 29 Jul 2015 07:00am EDT 

GlaxoSmithKline Plc:Has declared second interim dividend of 19 pence per share.Equivalent interim dividend receivable by ADR holders will be calculated based on exchange rate on Sept. 29.Ex-dividend date will be Aug. 13 ( Aug. 12 for ADR holders), with record date of Aug. 14 and payment date of Oct. 1.  Full Article

Pfizer Inc to acquire Nimenrix And Mencevax from GlaxoSmithKline Plc
Monday, 22 Jun 2015 07:08am EDT 

Pfizer Inc:Enters into agreement to acquire Nimenrix And Mencevax from Glaxosmithkline Plc.Says deal valued at about $130 million.Pfizer's legal advisors for the transaction were Ropes & Gray and Clifford Chance.  Full Article

Avalon Rare Metals Inc and Glaxosmithkline plc Launch Three New Companies with Series A Financing and R&D Support as Part of Ongoing Collaboration
Monday, 15 Jun 2015 08:00am EDT 

Avalon Rare Metals Inc and Glaxosmithkline plc:Ventures says launch of three new companies formed through its ongoing collaboration with gsk.Ventures-cadherx therapeutics,calporta therapeutics,to each get up to $10 million in series a financing,r&d support from Avalon ventures and gsk.Ventures-to provide adrenergics,cadherx,calporta with operational management consistent with its current portfolio strategy.Ventures-GSK has the option to acquire each of the companies upon the identification of a clinical candidate.Ventures-should gsk elect not to exercise acquisition option on any of the companies, ownership of those companies will remain with Avalon.  Full Article

Perrigo to buy portfolio of OTC brands from Glaxosmithkline
Tuesday, 2 Jun 2015 06:27am EDT 

Perrigo Company PLC:To acquire portfolio of leading otc brands from Glaxosmithkline.Says will acquire the following assets in an all-cash transaction in which the purchase price was not disclosed.Says transaction expected to be immediately accretive to 2015 adjusted EPS.Says transaction has been unanimously approved by the boards of directors of Perrigo and gsk.Portfolio includes European brands in the areas of nicotine replacement therapy, cold and flu, and cold sore management.Portfolio includes European brands in areas of nicotine replacement therapy, cold and flu, and cold sore management.  Full Article

Glaxosmithkline plc gives FY 2015 EPS below analysts' estimates - Conferance Call
Wednesday, 6 May 2015 09:30am EDT 

Glaxosmithkline plc:Expects FY 2015 core EPS to be down a high-teens percentage on a constant currency basis.Reported EPS of 0.9540 pounds in FY 2014.FY 2015 EPS of 0.8877 pounds - Thomson Reuters I/B/E/S.  Full Article

Glaxosmithkline PLC declares first interim dividend
Wednesday, 6 May 2015 07:00am EDT 

Glaxosmithkline PLC:Declares first interim dividend of 19 pence per share.The equivalent interim dividend receivable by ADR holders will be calculated based on the exchange rate on July 7.With effect from and including this dividend, an annual fee of $0.02 per ADS (or $0.005 per ADS per quarter) will be charged by the Depositary.The ex-dividend date will be May 14 (May 13 for ADR holders), with a record date of May 15 and a payment date of July 9.  Full Article

Glaxosmithkline plc and Theravance announces FDA approval of BREO ELLIPTA for treatment of adults with asthma in the US
Thursday, 30 Apr 2015 03:17pm EDT 

Glaxosmithkline plc and Theravance:Says that the US Food and Drug Administration (FDA) has approved BREO ELLIPTA (fluticasone furoate/vilanterol [FF/VI]) for the once-daily treatment of asthma in patients aged 18 years and older.Breo Ellipta is not indicated for the relief of acute bronchospasm.Breo is a fixed-dose combination of the inhaled corticosteroid (ICS) fluticasone furoate (FF) and the long-acting beta2-agonist (LABA) vilanterol (VI).Says two strengths, 100/25mcg and 200/25mcg, have been approved in the US for use in asthma, administered once-daily using the Ellipta dry powder inhaler.FDA issued a complete response letter related to the proposed use of Breo Ellipta in patients aged 12-17 stating that the data submitted do not show adequate risk-benefit to support the approval in these patients.FDA stated that additional data would be required to further demonstrate the safety and efficacy in this population.  Full Article

GlaxosmithKline Plc and Johnson & Johnson settle U.S. lawsuit over allergy ads - Reuters
Monday, 30 Mar 2015 10:21pm EDT 

GlaxosmithKline Plc:Agrees to settle a lawsuit by Johnson & Johnson accusing it of using false advertising at the start of the U.S. allergy season to grab market share - Reuters.The settlement was disclosed during a hearing in Manhattan federal court on March 30 in which two Johnson & Johnson units were expected to ask a judge to block Glaxo from making various claims about its allergy nasal spray Flonase.The terms were confidential.J&J units McNeil-PPC Inc and McNeil Consumer Healthcare filed the lawsuit on March 12, accusing Glaxo of making unsupported claims about Flonase at the expense of McNeil's drugs Benadryl and Zyrtec.  Full Article

GlaxosmithKline Plc completes partial sale of Aspen Pharmacare Holdings Ltd
Friday, 13 Mar 2015 03:00am EDT 

GlaxosmithKline Plc:Has agreed to sale of 28.2 mln ordinary shares in Aspen Pharmacare Holdings Ltd at a price of 372 South African rand per share , raising gross proceeds of about 10.5 bln South African rand.Following settlement of sale, it will hold 28.2 mln ordinary shares in Aspen Pharmacare Holdings Ltd, representing about 6.2 pct of issued share capital.Says gross proceeds of transaction are equivalent to 574 mln pounds at the prevailing exchange rate on March 12.Says proceeds from the transaction will be used for general corporate purposes.  Full Article

GlaxoSmithKline Plc intends to sell part holding in Aspen Pharmacare Holdings
Thursday, 12 Mar 2015 11:14am EDT 

GlaxoSmithKline Plc:Intends to sell about half of its 12.4 pct stake in Aspen Pharmacare Holdings Ltd.Says disposal will be through a placing of ordinary shares in Aspen to institutional investors.Offering is expected to comprise 28.2 mln Aspen ordinary shares equivalent to c.6.2 pct of Aspen's issued share capital.Offer price will be determined by means of an accelerated bookbuild offering process which is to start immediately.  Full Article

BRIEF-GSK CEO: UK competitive post-Brexit but questions over drug regulation, science

* Ceo says board looking at internal and external candidates to be new ceo, decision around end year